ARLINGTON, Virginia, United States, April 7, 2026
The ALS Association has issued a strong statement warning that the proposed FY27 federal budget could significantly threaten the future of ALS research, citing potential $5 billion funding cuts to the National Institutes of Health (NIH) and possible workforce reductions at both the NIH and Centers for Disease Control and Prevention (CDC). The organization emphasized that such reductions could slow scientific progress, disrupt clinical trials, and delay urgently needed therapies for patients living with amyotrophic lateral sclerosis (ALS).
NIH and CDC Funding Cuts Threaten Research Progress
The NIH is widely recognized as the backbone of biomedical research, supporting drug discovery, clinical trials, and critical data infrastructure for diseases like ALS. The ALS Association highlighted that reducing NIH funding at this stage would directly impact ongoing and future research programs, undermining years of scientific advancement.
Equally concerning are the proposed cuts to the CDC, which plays a vital role in tracking ALS prevalence, collecting public health data, and informing clinical research strategies. Any reduction in CDC capacity could weaken disease surveillance systems and limit the availability of data essential for developing new therapies.
The organization stressed that weakening these institutions during a period of significant scientific momentum could reverse progress, particularly as new technologies and clinical approaches are beginning to show promise in neurodegenerative disease treatment.
Advertisement
Impact on Clinical Trials and Drug Development
The ALS Association warned that cuts to federal funding and workforce capacity would directly affect clinical trial infrastructure, slowing the development of new and potentially life-saving treatments. ALS remains a rapidly progressive and fatal neurodegenerative disease, with most patients facing a life expectancy of three to five years after diagnosis and limited therapeutic options currently available.
Clinical trials for ALS therapies rely heavily on NIH funding, collaborative research networks, and public-private partnerships, all of which could be disrupted by budget reductions. The organization emphasized that delays in clinical research translate directly into delays in patient access to new treatments, making funding stability critical for maintaining progress.
Furthermore, workforce reductions at key agencies could slow regulatory processes, reduce research capacity, and hinder innovation, ultimately impacting the broader biopharmaceutical ecosystem.
Urgent Call for Policy Action and Continued Investment
The ALS Association is urging Congress and the Administration to prioritize sustained investment in ALS research, emphasizing that now is not the time to scale back funding but to accelerate progress toward effective treatments and a cure.
The organization reaffirmed its commitment to advocating for robust federal support, working alongside patients, researchers, and healthcare stakeholders to ensure that ALS remains a priority in national health policy.
With increasing scientific advancements in areas such as gene therapy, neuroprotection, and biomarker development, continued funding is essential to translate these discoveries into clinical breakthroughs and approved therapies.
The proposed FY27 budget cuts represent a critical risk to the future of ALS research and drug development, with potential consequences for clinical trials, regulatory progress, and patient access to new therapies. The ALS Association’s warning underscores the importance of strong federal investment in biomedical research, particularly for diseases with high unmet medical need and limited treatment options.
As the global scientific community continues to push toward innovative solutions for neurodegenerative diseases, sustained support for institutions like the NIH and CDC will be essential to ensure that progress is not only maintained but accelerated for the benefit of patients worldwide.
Source: Als association press release
